EUVIMEDEUVIMED entdecken
Crossref

The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma

Yoshinari Asai, Naoki Yanagawa, Mitsumasa Osakabe, Noriyuki Yamada, Ryo Sugimoto, Ayaka Sato, Kazuhiro Ito, Yoshihiko Koike, Takayuki Tanji, Minoru Sakuraba, Takashi Sato, Tamotsu Sugai

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Yoshinari Asai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Diagnostic Pathology, Iwate Medical University, Yahaba-cho, Shiwa-gun, Japan. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor‐associated macrophages (TAMs) are an immune component of the cutaneous malignant melanoma (CMM) microenvironment and affect tumor growth. TAMs can polarize into different phenotypes, that is, proinflammatory M1 and anti‐inflammatory M2 macrophages. However, the role of the macrophage phenotype in CMM remains unclear.

Methods

We examined 88 patients with CMM. Tissue microarrays were constructed, and the density of M1 and M2 macrophages was analyzed by immunohistochemistry. Immune cells coexpressing CD68 and phosphorylated signal transducer and activator of transcription 1 (pSTAT1) were considered M1 macrophages, whereas those coexpressing CD68 and c‐macrophage activating factor (c‐Maf) were defined as M2 macrophages. These TAMs were counted, and the relationships between the density of M1 and M2 macrophages and clinicopathological factors including prognosis were investigated.

Results

The CD68/c‐Maf score ranged from 0 to 34 (median: 5.5). The patients were divided based on the median score into the CD68/c‐Maf high (≥5.5) and low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansCutaneous Malignant MelanomaTumor-Associated MacrophagesAntigens, CDPrognosisTumor MicroenvironmentAntigens, Differentiation, Myelomonocytic

Stichwörter der Autor:innen

c-Mafcutaneous malignant melanomapSTAT1prognosistumor-associated macrophage

Substanzen

Antigens, CDAntigens, Differentiation, Myelomonocytic

Autor:innen und Institutionen

  • Department of Molecular Diagnostic Pathology, Iwate Medical University, Yahaba-cho, Shiwa-gun, Japan.
  • Department of Plastic, Aesthetic and Reconstructive Surgery, Iwate Medical University, Yahaba-cho, Shiwa-gun, Japan.

Zitieren

APA

Asai, Y., Yanagawa, N., Osakabe, M., Yamada, N., Sugimoto, R., Sato, A., Ito, K., Koike, Y., Tanji, T., Sakuraba, M., Sato, T., & Sugai, T. (2024). The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27487

Vancouver

Asai Y, Yanagawa N, Osakabe M, Yamada N, Sugimoto R, Sato A, et al. The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27487

BibTeX
@article{Asai2024,
  author = {Asai, Yoshinari and Yanagawa, Naoki and Osakabe, Mitsumasa and Yamada, Noriyuki and Sugimoto, Ryo and Sato, Ayaka and Ito, Kazuhiro and Koike, Yoshihiko and Tanji, Takayuki and Sakuraba, Minoru and Sato, Takashi and Sugai, Tamotsu},
  title = {The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27487}
}
Kostenlos starten →